The Manufacturers Life Insurance Company trimmed its position in Azenta, Inc. (NASDAQ:AZTA - Free Report) by 76.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,936 shares of the company's stock after selling 29,240 shares during the period. The Manufacturers Life Insurance Company's holdings in Azenta were worth $447,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Picton Mahoney Asset Management grew its stake in Azenta by 305.7% in the fourth quarter. Picton Mahoney Asset Management now owns 706 shares of the company's stock worth $35,000 after purchasing an additional 532 shares during the period. Headlands Technologies LLC purchased a new stake in Azenta in the fourth quarter worth $40,000. Covestor Ltd grew its stake in Azenta by 64.2% in the fourth quarter. Covestor Ltd now owns 2,043 shares of the company's stock worth $102,000 after purchasing an additional 799 shares during the period. KBC Group NV grew its stake in shares of Azenta by 48.5% in the fourth quarter. KBC Group NV now owns 2,137 shares of the company's stock worth $107,000 after acquiring an additional 698 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Azenta in the fourth quarter worth $110,000. 99.08% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
AZTA has been the topic of a number of recent research reports. TD Cowen raised Azenta to a "hold" rating in a research note on Thursday, February 27th. Evercore ISI increased their target price on Azenta from $50.00 to $52.00 and gave the stock an "in-line" rating in a research note on Thursday, February 6th. Finally, Needham & Company LLC cut their target price on Azenta from $59.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th.
View Our Latest Stock Report on AZTA
Azenta Stock Down 3.7%
Shares of NASDAQ AZTA traded down $1.03 during trading on Friday, reaching $27.00. The company had a trading volume of 865,146 shares, compared to its average volume of 689,311. Azenta, Inc. has a 12-month low of $23.91 and a 12-month high of $63.58. The stock has a market cap of $1.24 billion, a PE ratio of -9.06 and a beta of 1.64. The business's 50-day moving average is $29.05 and its 200 day moving average is $41.01.
Azenta (NASDAQ:AZTA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.04). Azenta had a negative net margin of 24.91% and a positive return on equity of 1.25%. The firm's quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.06 EPS. On average, analysts anticipate that Azenta, Inc. will post 0.53 earnings per share for the current year.
About Azenta
(
Free Report)
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Recommended Stories

Before you consider Azenta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.
While Azenta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.